Welcome to our dedicated page for Endo International plc news (Ticker: ENDP), a resource for investors and traders seeking the latest updates and insights on Endo International plc stock.
Endo International plc (OTC: ENDPQ) is a leading specialty pharmaceutical company dedicated to improving the lives of patients through innovative and high-quality therapies. With a global team of passionate professionals, Endo transforms insights into effective treatments and ensures these are available to those who need them most.
Endo's core business revolves around the development, manufacturing, and marketing of branded and generic pharmaceutical products. The company focuses on areas such as pain management, urology, endocrinology, and oncology, catering to various unmet medical needs. Over the years, Endo has built a robust portfolio of products that enhance the quality of life for patients worldwide.
Recent Achievements and Projects:
- On September 21, 2023, Endo announced the presentation of data from clinical studies of collagenase clostridium histolyticum (CCH) for treating plantar fibromatosis at the American Orthopaedic Foot & Ankle Society's annual meeting. These studies showed improvement in nodule hardness and patient satisfaction, with a consistent safety profile.
- Endo has completed a Phase 2 study of CCH and anticipates beginning the pivotal Phase 3 program later this year. This effort underscores Endo's commitment to developing nonsurgical treatment options for conditions like plantar fibromatosis.
Endo's financial condition is currently under strategic restructuring, including Chapter 11 proceedings, aimed at addressing the company's liabilities and ensuring long-term viability. Despite these challenges, Endo continues to prioritize its mission of delivering life-enhancing therapies.
Endo's partnerships and collaborations play a crucial role in its success. By working with healthcare professionals, research institutions, and other industry stakeholders, Endo stays at the forefront of pharmaceutical innovation and effectively meets market demands.
For more information about Endo and its latest news, visit www.endo.com or connect with the company on LinkedIn.
On October 22, 2021, Endo International plc (NASDAQ: ENDP) shared new post-hoc data from two Phase 3 studies of XIAFLEX® for Peyronie's disease at the SMSNA annual meeting. The analysis highlighted the significance of patient adherence and incremental benefits from each of the four treatment cycles, suggesting that consistent treatment improves outcomes for men, even for those initially considered non-responders. XIAFLEX is the only FDA-approved non-surgical treatment for this condition, affecting an estimated 1 in 10 men in the U.S.
Endo International (NASDAQ: ENDP) will release its Q3 2021 financial results on November 4, 2021. Following the earnings announcement, the company's senior management will host a conference call on November 5, 2021 at 7:30 am ET. Investors can access the call via U.S./Canada dial-in (866) 497-0462, or internationally at (678) 509-7598 using passcode 6052178. A replay will be available from November 5, 2021, to November 12, 2021. For more details, visit endo.com.
Endo International (NASDAQ: ENDP) announced a $7.5 million agreement to settle all opioid-related claims with the Louisiana Attorney General's office. The settlement requires 100% participation from Louisiana’s political subdivisions by October 28, 2021, and includes no admission of wrongdoing by Endo. This effort is part of Endo's broader strategy to resolve ongoing opioid litigation while pursuing other strategic options. The company aims to help address Louisiana’s opioid crisis through these funds.
Endo International announced that Par Pharmaceutical has begun shipping the first FDA-approved generic version of Pfizer's Chantix (varenicline) in the U.S. This significant milestone follows the final approval of its Abbreviated New Drug Application. Estimated sales of Chantix were approximately $1 billion for the 12 months ending June 30, 2021. Jon Holden, Endo's Senior VP, emphasized the importance of this launch in expanding Par's product portfolio and providing reliable generics to the market.
Endo International plc (NASDAQ: ENDP) announced a settlement regarding three opioid-related lawsuits in New York, resolving claims against its subsidiaries for $50 million. This settlement severs Endo from an ongoing jury trial that began in June 2021, without admitting any wrongdoing. The company aims for a global settlement for remaining opioid claims and is exploring strategic alternatives if this is not achieved. The settlement should not be seen as a precedent for other cases or claims.
Endo International (NASDAQ: ENDP) expressed disappointment over the U.S. District Court's ruling favoring Eagle Pharmaceuticals regarding VASOSTRICT® patent litigation. The court ruled there was no infringement on Endo's patents by Eagle's proposed product but did not address the validity of these patents. Endo plans to appeal the decision, highlighting concerns over the court's interpretation of conflicting appellate case law on product testing data. The company remains committed to defending its intellectual property rights.
Endo International plc (NASDAQ: ENDP) reported second-quarter 2021 results with total revenues of $714 million, a 4% increase from $688 million in Q2 2020. The Branded Pharmaceuticals segment saw strong growth, with XIAFLEX® revenues rising to $111 million from $34 million year-over-year. However, the company reported a net loss of $15.5 million and a diluted net loss per share of $0.04. Endo adjusted its full-year financial guidance, reflecting uncertainties related to the ongoing COVID-19 pandemic.
Endo International plc (NASDAQ: ENDP) announced a definitive Settlement Agreement resolving an opioid-related case, Staubus, et al. v. Purdue Pharma, L.P., et al., in Sullivan County, Tennessee. The settlement, totaling $35 million, resolves all related claims from nine counties and eighteen towns, with no admission of wrongdoing by Endo. This agreement is designed to absolve Endo from related lawsuits but should not set a precedent for other claims. The financial impact is significant, although details regarding how the payment will be distributed among plaintiffs were not disclosed.
Endo International plc (NASDAQ: ENDP) reported promising Phase I results for collagenase clostridium histolyticum (CCH) as a treatment for plantar fibromatosis at the American Podiatric Medical Association Annual Scientific Meeting. The study involved 24 patients and indicated that CCH was generally well tolerated, with no serious treatment-related adverse events. Over 72% of participants expressed satisfaction with the treatment. This study marks a potential shift for Endo into the podiatric market and builds on their commitment to advancing nonsurgical treatment options.
FAQ
What does Endo International plc do?
What recent achievements has Endo announced?
What are Endo's core therapeutic areas?
What is plantar fibromatosis?
What is Endo’s financial situation?
How is Endo addressing unmet medical needs?
Where can I find more information about Endo?
What is CCH and what is its significance?
Is CCH approved for treating plantar fibromatosis?
What partnerships does Endo engage in?
